Annals of Oncology Advance Access originally published online on February 25, 2005
Annals of Oncology 2005 16(4):579-584; doi:10.1093/annonc/mdi122
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
© 2005 European Society for Medical Oncology
Original articles |
The significance of skeletal-related events for the health-related quality of life of patients with metastatic prostate cancer
1 Center for Clinical and Genetic Economics, Duke Clinical Research Institute, Duke University Medical Center, Durham, NC, USA; 2 Centre Hospitalier de l'Université de Montréal, Hôpital Notre-Dame, Montréal, Québec, Canada; 3 Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA
* Correspondence to: Dr K. P. Weinfurt, Center for Clinical and Genetic Economics, Duke Clinical Research Institute, PO Box 17969, Durham, NC 27715, USA. Tel: +1-919-668-8101; Fax: +1-919-668-7124; Email: kevin.weinfurt{at}duke.edu
Background: We examined the clinical relevance of skeletal-related events (SREs) for health state preferences, pain and health-related quality of life in patients with advanced prostate cancer and a history of bone metastases.
Patients and methods: Data were from a clinical trial of zoledronic acid versus placebo in the treatment of SREs associated with advanced prostate cancer metastatic to bone. Patients (n=248) were included if they experienced an SRE during the study. Outcome measures were assessed at fixed intervals. We used mixed-effects models to estimate changes in outcomes after each patient's first SRE.
Results: There were clinically meaningful and statistically significant declines in physical well-being after: radiation and pathologic fractures; functional well-being after radiation; and emotional well-being after radiation and pathologic fractures. There also were meaningful and significant declines in preference and utility scores after radiation and fracture. Pain intensity declined after radiation, but not after other SREs; no other pain measure changed substantively.
Conclusions: SREs have important and significant effects on measures of health-related quality of life in men with prostate cancer. Treatments that prevent SREs may not demonstrate corresponding effects on outcomes if the effects of SREs occur between scheduled outcome assessments. Implications for trial design are discussed.
Key words: antineoplastic agents, bone neoplasms, diphosphonates, prostatic neoplasms, quality of life, research design
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  M. Aapro, P. A. Abrahamsson, J. J. Body, R. E. Coleman, R. Colomer, L. Costa, L. Crino, L. Dirix, M. Gnant, J. Gralow, et al. Guidance on the use of bisphosphonates in solid tumours: recommendations of an international expert panel Ann. Onc., March 1, 2008; 19(3): 420 - 432. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. P. Weinfurt, K. J. Anstrom, L. D. Castel, K. A. Schulman, and F. Saad Effect of zoledronic acid on pain associated with bone metastasis in patients with prostate cancer Ann. Onc., June 1, 2006; 17(6): 986 - 989. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. Tanvetyanon Reply to the article "The significance of skeletal-related events for the health-related quality of life of patients with metastatic prostate cancer" by K. P. Weinfurt et al. (Ann Oncol 2005; 16: 579-584) Ann. Onc., October 1, 2005; 16(10): 1712 - 1713. [Full Text] [PDF]
|
|
|
|
|
|
J. Bernhard Timing of quality of life assessment in cancer clinical trials: fine tuning remains a challenge Ann. Onc., April 1, 2005; 16(4): 523 - 524. [Full Text] [PDF]
|
|